Our results further suggest that the endocrine IGF/insulin system becomes more important for growth in the late stages of (metastasized) colorectal cancer, suggesting that a difference in response to insulin/IGFs may be a property acquired with metastatic spread of colon cancer cells to secondary sites. The gene discussed is IGF1; the disease is colorectal cancer.